🔗 Share this article

Given that America continues making unprecedented changes to its immunization guidelines, a particular individual appears in a surprising turn: Høeg, a US-based sports physician and public health researcher who rose to prominence by questioning Covid vaccinations throughout the pandemic and has concentrated on possible fatalities following COVID-19 vaccination in her short tenure at the Food and Drug Administration.

Planned Shifts to Childhood Vaccine Schedule

Agency leaders had intended to announce radical changes to the pediatric vaccine schedule in December, bringing the US with Denmark’s immunization schedule, sources say – a significant shift that would place the US out of alignment with many the global community with little proof for benefit. The announcement has been postponed until the new year.

Instead of the top vaccines chief, Høeg is set to present at the meeting. She was just designated acting director of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth individual to head the center this year.

A Shift at the FDA

This interim role may indicate a tighter collaboration between the drug and vaccine centers as Dr. Høeg and Dr. Prasad solidify control at the regulatory agency – and it signals a increased emphasis upon rolling back already-approved immunizations at the FDA.

Høeg has often pushed for discontinuing specific childhood shot schedules in the US so as to align more like Denmark's approach, a nation with comprehensive healthcare and a citizenry roughly the size of the state of Wisconsin.

To date comments, she has kept her attention on vaccination policy – traditionally the purview of Prasad, head of the FDA’s vaccine center – rather than medication approval.

Concerns Over Qualifications

The appointee has no apparent background in medication creation, approval processes or administrative roles, which has been typical for previous heads of the biologics center. She has served at the FDA as a senior adviser to the FDA chief and CBER since spring.

“She appears not to have the requisite experience” for overseeing the drug-regulation department, stated a neurologist and psychiatrist. “She’s never run a clinical trial. She is not versed in leading a large organization. She is not an expert in drug approvals.”

Previous heads of the center would “understand laws and regulations and the science of medication creation”, said Janet Woodcock. “Objectively, she has not acquired the kind of background that previous people who ran CBER have had.”

This division has an enormous range of responsibilities at the agency, she emphasized.

“The public just pays attention on the innovative therapies, but the generic program clears a multitude of generic drugs. There’s a biologic copycat branch, non-prescription drug unit and more, and every single one must be managed,” she noted. “The area you don’t keep your eye on, that’s the thing that I always told people is going to come back to haunt you.”

Additionally, a major management aspect to the position, which manages more than 5,000 employees. “It’s a massive administrative position, if you execute it properly,” the former official concluded.

Official Statement and Controversial Policies

Regarding questions about Dr. Høeg's qualifications and whether this selection indicates greater collaboration among regulatory chiefs on immunizations, a spokesperson said that the “inquiries stem from inaccurate presumptions”.

“Her resume aligns with the duties of her job,” the representative stated, citing the months Dr. Høeg spent advising the FDA commissioner on “medication safety and regulatory science, including computational safety modeling and shot safety tracking”.

As acting director, Høeg assumes responsibility for the commissioner’s new expedited review system, a contentious rapid drug-approval program that apparently concerned her former heads. “By what process are these medications being picked for this fast-track system? Who is making the calls?” Dr. Howard questioned. “There is a lot of secrecy happening at the agency right now.”

Broadly speaking, he said, “the Food and Drug Administration seems to be moving towards less stringent oversight of pharmaceuticals, except for vaccines.”

Documented History on Immunizations

Regarding vaccines, Dr. Høeg has a clearer, if problematic, past, some experts observe. She published a analysis using unverified crowd-sourced reports to estimate the rate of heart inflammation following Covid immunization. She counseled the Florida surgeon general Joseph Ladapo, who allegedly have modified findings to indicate Covid vaccinations are riskier than they are.

Part of her “desired changes” for the incoming administration encompassed altering rules for recently developed shots and halting “optional” immunizations, she said post-election on a podcast. At the agency, Høeg has reportedly floated the idea of excluding young men from obtaining COVID-19 vaccines.

“She’s an thorough ideologue who starts off with her preconceived notions and tailors the evidence to accommodate the evidence in a very disingenuous, untruthful way,” Dr. Howard said.

Consolidating Power and a “Push for Payback”

Dr. Høeg joined fellow dissenters, {like|